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Abstract
Ketamine was discovered in 1964 by merging a ketone with an amine. Patients 
described feeling disconnected like they were floating in outer. Thus, it was char-
acterized as a dissociative anesthetic. It is a unique drug that expresses hypnotic, 
analgesic, and amnesic effects. No other drug used in clinical practice produces 
these three important effects at the same time. Its newly found neuroprotective, 
anti-inflammatory, antitumor effects and low dose applications have helped to 
widen the clinical profile of ketamine. Ketamine as an analgesic adjunct in chronic 
pain patients is currently being researched. Combined use of ketamine and an 
opiate analgesic has been found to provide good perioperative pain control with 
reduction in symptoms such as nausea and vomiting, sedation, and respiratory 
insufficiency.
Keywords: ketamine, pain, dissociative anesthesia, NMDA receptors, ketamine 
physiology, ketamine side effects, ketamine as induction agent, ketamine for 
maintenance of anesthesia, ketamine contraindications, perioperative analgesia, 
 anti-inflammation, sub anesthetic dose of ketamine
1. Introduction
The story of ketamine began in the 1950s in Park-Davis and Company’s 
Laboratories as the search for a cyclohexylamine that would serve as an “ideal” 
anesthetic agent. This new agent would also have analgesic properties. In March 1956, 
Dr. Harold Maddox synthesized a compound [N-(1-phenyl-cyclohexyl)-piperidine] 
known as phencyclidine (PCP) using a new chemical organic Grignard reaction [1]. 
Several experiments were performed at Parke-Davis labs and Wayne State University; 
both on animals and in human trials. These experiments made it clear that phency-
clidine was capable of producing a potent analgesic and cataleptic state defined as a 
“characteristic akinetic state with a loss of orthostatic reflexes, but without impair-
ment of consciousness, in which the extremities appear to be paralyzed by motor and 
sensory failure” [2, 3]. After administering the drug, patients had an increase in blood 
pressure, respiratory rate, and minute volume while corneal and laryngeal reflexes 
were conserved. However, increased salivation and nystagmus were noted. With these 
findings, PCP was deemed to be a useful agent in the setting of anesthesia. However, 
with further studies, it became apparent that there was a profound and prolonged 
state of emergence delirium. This discovery would hinder the widespread use of PCP 
and begin the search for a new related compound [1, 3].
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Finally, in 1962, Dr. Calvin Stevens was successfully synthesized a derivative of 
PCP – CI-581 or ketamine – which was selected to undergo human trials. On August 
3 1964, the first human intravenous subanestheic dose of ketamine was successfully 
administered to volunteer prisoners at Jackson prison in Michigan [1]. About one-
third of the patients had reported adverse effects of psychotic reactions which they 
described as a feeling of floating in outer space and having no feelings in their limbs. 
Due to this effect, Domino’s wife Toni termed it “dissociative anesthesia” originat-
ing the concept of dissociative anesthesia [1, 4]. Dissociative anesthesia would later 
bed deifined as a state of electrophysiological and functional dissociation between 
thalamocortical and limbic systems. It was then concluded that ketamine is a potent 
analgesic and anesthetic with lower potency and shorter duration of action than 
PCP. Finally, in 1969, ketamine hydrochloride became available as a prescription 
drug under the name of Ketalar and a year later was approved by the US Food and 
Drug Administration [2, 3].
Unfortunately, the popularity of ketamine declined as it caused hallucinations 
and psychotic reactions that were an unpleasant experience for patients. However, 
in the early 1990s, ketamine made a come-back due to the peak of high-dose opioid 
anesthesia [3]. Ketamine is becoming widely used among anesthesiologists for both 
induction and maintenance in anesthetic and subanesthetic doses. Commonly it is 
used in combination with diazepam, midazolam, or propofol to help reduce halluci-
nations, psychotic reactions, and emergence delirium [1]. A recent interest has also 
sparked in opioid free anesthesia using ketamine. Contrary to yesteryears practice, 
today ketamine is widely used for a variety of different procedures for its valuable 
anesthetic, analgesic, and even amnestic properties, as we will discuss throughout 
this chapter.
2. Chemistry and pharmacology
Ketamine’s chiral carbon center allows for the existence of two different steric 
configurations - S(+) and R(−) isomers. Each isomer has varying anesthetic, anal-
gesic, dysphoric, and sympathomimetic properties. Several studies have shown that 
the S(+) isomer is more potent and has a higher NMDA affinity when used intraop-
eratively for anesthesia compared to the R(−) isomer. In addition, the S(+) isomer 
causes lower cardiac stimulation, less spontaneous motor activity, better analgesia, 
faster recovery, fewer psychotomimetic side effects, and decreased incidence of 
emergence delirium [1, 2].
Ketamine primarily works by inhibition of NMDA receptors and has two 
different mechanisms through which it exerts its function. NMDA receptors are 
excitatory amino acid receptors that have been implicated in pain [5]. The first 
mechanism of NMDA antagonism is as a channel blocker. The second mechanism 
is through an allosteric mechanism that decreases the opening frequency of the 
NMDA channel. It can also exert its effect through a variety of other mechanisms 
such as inhibition of L-type calcium channels, BK channels, HCN channels, and 
voltage-gated sodium channels. Other mechanisms of actions include monoamine 
blockade and inhibition of serotonin reuptake [2].
Ketamine has a slow off-rate compared to other anesthetic agents. This means 
that it continues to exert its effect even after glutamate; the substrate for NMDA 
receptors, has dissociated. This allows for a better anesthetic effect.
Ketamine has a high lipid solubility allowing it be rapidly taken up by the brain 
and redistributed to highly perfused tissue with a distribution half-life between 10 
and 15 minutes [2]. Its metabolism is highly dependent on the liver using the cyto-
chrome P450 system. Ketamine can be converted into active or inactive metabolites, 
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which are then further hydroxylated to increase water solubility through various 
CYP450 enzymes. The metabolites are then renally eliminated [1, 6].
Research has shown that ketamine has a dose dependent effect. In this chapter, 
we will focus on anesthesia and analgesia. Analgesic effects are seen at levels of 
100–160 ng/ml. Induction of anesthesia is usually achieved at 9000–25000 ng/ml 
and can be maintained with 2000–3000 ng/ml. Ketamine’s half-life at anesthetic 
doses is approximately 79 minutes, and its actions decrease when the drug redis-
tributes from the brain into other tissue. The threshold between consciousness and 
emergence from anesthesia is 1000 ng/ml. The psychic state is usually seen with 
doses between 50 and 200 ng/ml. The onset and duration of these psychedelic 
effects varies based on the route of administration [1, 6].
Because ketamine is both water and lipid soluble, it can be administered 
intravenously, intramuscularly, orally, and sublingually. However, due to its sig-
nificant first pass metabolism oral administration yields very little bioavailability. 
Intravenous administration is the preferred route of administration as it allows for 
100% bioavailability. Recommended doses, shown in Table 1, are between 1 and 
4.5 mg/kg over the course of 60 seconds for induction. For general maintenance 
1–6 mg/kg/hr. and 0.4–1 mg/kg/hr. for continuous sedation is recommended [6]. 
Ketamine can be given intramuscularly that has a 93% bioavailability and is useful 
in emergencies, uncooperative patients and burn patients. When administered 
intramuscularly higher doses, between 6.5–13 mg/kg, are needed. For subanesthetic 
doses the intravenous dose is between 0.2–0.8 mg/kg and 2–4 mg/kg if given 
intramuscularly [2].
Table 1 summarizes the various suggested doses of ketamine administration 
depending on route, phase and administration method of anesthesia.
For review, Induction is the transition from an awake state to an anesthetized 
state with a sole agent such as ketamine or propofol or a combination of drugs 
[2]. Maintenance involved sustaining this anesthetic [7]. The role of ketamine in 
induction and maintenance in the practice of anesthesia will be discussed later in 
this chapter.
3. Use of ketamine in anesthesia
In the first ever human trial done with ketamine, a 1–2 mg/kg dose was given to 
patients, which resulted in analgesia and anesthesia with an onset time of one min-
ute and lasted for about five to ten minutes. Within one to two hours the patients 
were back to their initial state. An increase in blood pressure and heart rate, hyper-
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depression was also seen but returned to baseline within seven minutes. Even so, 
reflexes were preserved throughout. No labs were significantly affected. However, 
during the recovery period, as with PCP, psychic reactions, mood and affect 
alterations were observed but laster for a shorter duration and were less severe than 
the reaction with PCP that subsided within 30 mins after awakening. Many of the 
effects that were seen with ketamine were not seen with the anesthetics used com-
monly during that time period [4]. This led to the conclusion that ketamine results 
in a short-acting and effective induction of anesthesia and analgesia.
Ketamine has been shown to be safe and effective for maintenance sedation 
in several studies. It decreases airway resistance, improves dynamic compliance, 
preserves functional residual capacity, tidal volume, and minute ventilation [7]. 
Another advantage observed was that with ketamine, pharyngeal and laryngeal 
reflexes were conserved. In addition, ketamine provides an additional benefit in 
patients with refractory bronchospasms as it decreases audible wheezes, broncho-
dilator requirements, and hypercarbia making it the drug of choice in patients with 
bronchospasms [7]. Furthermore, in patients with refractory status asthmasticus, it 
helps reduce the need for initiation of mechanical ventilation [8]. Ketamine is also a 
popular induction agent [2]. For induction, ketamine is usually used in combination 
with other agents such as propofol or diazepam for reduction in emergence excite-
ment, or dissociative effects that often result when ketamine is used [8].
Since ketamine is known for its ability to cause dissociative anesthesia, it 
has been hypothesized to be particularly beneficial for painful or distressing 
procedures. For example, endotracheal intubation using ketamine has been suc-
cessful in some cases with the added advantage of maintaining or even increasing 
cardiorespiratory tone. We will discuss four methods for endotracheal intubation 
that have been evaluated. In delayed sequence intubation, dissociative doses of 
ketamine are given to allow the patient to enter an unconscious state so that proper 
preparation and pre-oxygenation can be taken before a paralytic is given. With this 
method, there were reduced adverse events and improved oxygen saturation. In 
ketamine-only breathing intubation, a dissociative dose of ketamine monotherapy 
is used in spontaneously breathing patients. This strategy seems to be useful in 
patients with anatomically difficult airways, physiologic limitations and profound 
acidosis. With traditional rapid sequence intubation, ketamine was given with the 
traditional rapid sequence intubation protocol. In review, rapid sequence intuba-
tion is when an induction agent and a paralytic are administered simultaneously 
during endotracheal intubation without the need for bag mask ventilation. This 
method has an advantage when apnea caused by the paralytic agent is not a concern. 
Finally, in ketamine for post-intubation analgesia and sedation, ketamine given 
after intubation provides two benefits - stimulating heart rate and blood pressure 
and analgesic and sedative properties. This allows for the reduction of conventional 
sedative use which has been linked to prolonged ICU stay and delirium. Although 
advantages have been noted, using ketamine for airway management using these 
strategies should be done with careful planning and caution, as there still is limited 
evidence [9].
4. Effects of ketamine use
A major advantage of ketamine, unlike many other anesthetic agents, is hemo-
dynamic stability. It is also generally well tolerated in both pediatric and geriatric 
patients. As mentioned previously, ketamine when given in a combination with pro-
pofol for induction significantly improves hemodynamic stability within the first 
ten minutes [10]. This advantage makes ketamine extremely beneficial in managing 
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hemodynamically unstable patients such as those who have suffered severe trauma. 
For example, in which ketamine has been useful is in the management of burn 
patients especially during the acute phase of injury. During the acute phase, the 
burn victims are undergoing significant fluid shifts leading to cardiovascular and 
respiratory insufficiency [11].
4.1 Anti-inflammatory effect
Inflammation is a normal mechanism that the body uses to fight infection caused 
by viruses and bacteria. This mechanism is initiated by pro-inflammatory cytokines 
that are released by the immune cells. These pro-inflammatory cytokines (IL-1, 
IL-6, IL-8, IL-12, IFN-γ, IL-18, and Tumor Necrosis Factor (TNF) [12]. However, 
inflammation can also be disadvantageous in that it can lead to pain and swelling 
in the acute setting. Concentrations of proinflammatory cytokines during the 
perioperative period may significantly impact surgical outcome. Ketamine has been 
shown to modulate the perioperative cytokine response and plays a significant anti-
inflammatory role. It inhibits the systemic response without affecting the healing 
process that is necessary during the postoperative state [12]. One such mechanism 
is the reduction of leukocyte migration through endothelial monolayers. It is well 
studied that neutrophils play a key role in defense against foreign pathogens. Upon 
activation, neutrophils need to cross endothelial cell layers. Researchers investi-
gated the effects of ketamine on leukocytes and endothelial cells independently 
and together. In a dose-dependent fashion, ketamine suppressed migration when 
leukocytes alone were treated. Interestingly, when the endothelial cells were treated 
with ketamine, there was no significant reduction in migration. However, when 
both leukocytes and endothelial cells were treated, the suppression in migration was 
much higher than when only leukocytes were treated [13]. One possible mechanism 
that may achieve this is is the inhibition of the up-regulation of CD18 and CD26L on 
neutrophils. CD18 and CD26L are stimulated during inflammation and are impor-
tant cell surface markers for adhesion of neutrophils to endothelial cells promoting 
neutrophil migration [14].
It has also been suggested that this effect might be mediated by the suppression 
of microglial activation in the CNS or the inhibition of large conductance calcium 
activated potassium channels in the microglia. Specifically, there is a reduction 
in postoperative pro-inflammatory cytokines such as serum IL-6, TNF-a, nuclear 
factor kb, CRP and nitric oxidase synthase [15]. In addition, an increase in post-
operative serum IL-10 levels, an anti-inflammatory cytokine. Ketamine was also 
shown to impair neutrophil chemotaxis, inhibit superoxide radical production, 
inhibit differentiation of immature dendritic cells, and increase Treg cell concentra-
tion [16]. Ketamine may also alter the oxidative stress response in patients. When 
ketamine was administered, patients had lower total thiol molecules and a lower 
total antioxidant capacity. They also had higher lipid peroxidation, and higher 
superoxide dismutase and glutathione peroxidase activity [17].
4.2 Psycho modulator effects
Ketamine has several effects on brain activity that can be monitored by EEG. 
When subanesthetic doses are given, the complexity of EEG changes is elevated 
relative to the baseline. At anesthetic doses the pattern alternates between a high 
and low complexity. Eventually the pattern stabilizes at a high complexity that is 
similar to baseline. This shows that ketamine can induce a fragmented state that 
shows alternating patterns of conscious and anesthetic states. A bolus of ketamine 
induces unconsciousness causing a change from slow waves to a gamma-burst 
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wave pattern on the EEG, which later evolved into a stable gamma pattern most 
likely due to decreasing plasma ketamine levels [18]. In addition, in hippocampal 
and cortical neurons, ketamine can increase activity of extrasynaptic GABA-a 
receptors which generate tonic inhibitory currents. Ketamine has been shown 
to increase potency of low concentration of GABA at these receptors as well 
[19]. Secondary effects on the dopamine system due to ketamine alters the fir-
ing rate of mesocortical and mesolimbic dopamine neurons causing an increase 
in extracellular dopamine in the striatum and prefrontal cortex which has been 
hypothesized to be a contributing factor the psychotic-like behaviors observed 
with ketamine [20].
Another interesting aspect of ketamine is that its effect varies depending on 
other anesthetic agents used with it or if it is used as a sole agent. For example, 
in a study done with rats it was found that when ketamine was added to ongoing 
sevoflurane or propofol, on EEG there was either no change or a shift to higher 
frequencies. However, when ketamine was given alone there was a simultaneous 
increase in both lower and higher frequencies. Also, when ketamine is used as a 
sole anesthetic agent patients can experience dissociative effects. However, at the 
same time ketamine is also found to be neuroprotective in preventing or mitigat-
ing postoperative delirium. This might explain why ketamine is being used both as 
an experimental model of psychiatric diseases as well as a proposed treatment for 
psychiatric diseases [21].
Ketamine’s unusual cataplectic properties make it a dissociative anesthetic. At 
low doses, it causes alteration in visual and auditory stimuli and feelings of detach-
ment from one’s surroundings that manifest themselves as delirium, hallucinations, 
delusions, and confusion [20]. This leads to a potential for abuse and explains why 
ketamine is a class III-controlled substance and often referred to as “Special K”. 
Long term effects of repeated ketamine use may lead to flashbacks, attentional 
and other cognitive dysfunctions, and decreased sociability. On the other hand, 
its continued use is reinforced by the other psychotropic effects. Therefore, 
some anesthesiologist may choose to avoid ketamine especially when it comes to 
patients with Post Traumatic Stress Disorder (PTSD) [15]. However, a recent study 
presented a trial of repeated intravenous ketamine administration for patients 
with PTSD. Infusion of ketamine demonstrated a clear superiority in reduction 
of symptoms compared to midazolam. More research on this aspect of ketamine 
is needed to help guide its use in anesthesia in patients with PTSD [10]. Caution 
should also be used when using ketamine for anesthesia in schizophrenic patients. 
This is because ketamine has been found to induce hallucinations, delusions and 
thought disorders, resembling an active schizophrenic episode of their illness. 
These episodes are also resistant to haloperidol, the drug traditionally used to treat 
active episodes [22].
Interestingly, ketamine and its metabolites modulate distinct neural circuits to 
produce dissociation and analgesia. The channel blocking effect of ketamine at the 
NMDA receptors may partially explain its dissociative properties. This is because 
ketamine blocks excitatory NMDA receptors on fast-spiking cortical interneurons 
more effectively than those on pyramidal neurons. This results in markedly dysreg-
ulated pyramidal neuronal activity. The relative inactivity of cortical interneurons 
leads to glutamate-mediated pyramidal–pyramidal neuronal facilitation. Consistent 
with this notion, lamotrigine, an antiepileptic medication that reduces cortical 
glutamate release and pyramidal neuron facilitation, suppresses the dissociative 
properties of ketamine. In the same fashion, midazolam reduces pyramidal neuron 
facilitation by downstream activity resulting from binding at gamma amino-butyric 
acid receptors on pyramidal neurons [23]. This could explain why ketamine causes a 
feeling of dissociation when it is used as an anesthetic agent.
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4.3 Neuroprotective effects
There is also evidence that ketamine has neuroprotective effects. It is thought 
that this occurs due to the inhibition of calcium influx that occurs with ketamine 
administration. This calcium influx inhibition helps prevent ischemia and apoptosis 
providing a protective benefit to neurons. When ketamine was compared with 
other anesthetic agents such as midazolam, fentanyl, and propofol there was a 
reduction of spreading depolarizations with ketamine administration. Spreading 
depolarizations can cause neurovascular decoupling and potentiate the secondary 
phase of brain damage. Therefore, it is hypothesized that when ketamine is used, 
the suppression of these spreading depolarization allows for the maintenance of 
the electrochemical gradient and prevents neurovascular decoupling. This works 
together to have neuroprotective effects. However, the opposite effects could occur 
if repeated high doses are given as ketamine has the potential to cause neurotoxicity 
particularly in the developing brain. When ketamine is given in repeated high doses, 
there is an increase in a subunit of NMDA receptors, NR1. This allows the opposite 
effect, increasing the influx of calcium leading to apoptosis [8].
Traditionally, it was thought that ketamine increased intracranial pressure. 
In recent years, this theory has been rejected. Ketamine has successfully been 
used to reduce intracranial pressure. One study examined the effects of ketamine 
on intubated and sedated pediatric population at a regional trauma center with 
elevated ICP >18 mmHg resistant to first tier therapies. The results of 82 ketamine 
administrations in 30 patients were analyzed. Overall, following ketamine admin-
istration, ICP decreased by 30% (from 25.8 ± 8.4 to 18.0 ± 8.5 mm Hg) (p < 0.001) 
and Cerebral Perfusion Pressure (CPP) increased from 54.4 ± 11.7 to 58.3 ± 13.4 mm 
Hg (p < 0.005). In Group 1, ICP decreased significantly following ketamine admin-
istration and increased by >2 mm Hg during the distressing intervention in only 
1 of 17 events. In Group 2, when ketamine was administered to lower persistent 
intracranial hypertension, ICP decreased by 33% (from 26.0 ± 9.1 to 17.5 ± 9.1 mm 
Hg) (p < 0.0001) following ketamine administration. They concluded that in 
ventilator-treated patients with intracranial hypertension, ketamine effectively 
decreased ICP and prevented untoward ICP elevations during potentially distress-
ing interventions, without lowering blood pressure and CPP. In addition, these 
results refute the notion that ketamine increases ICP. Ketamine is a safe and effec-
tive drug for patients with traumatic brain injury and intracranial hypertension, 
and it can be used safely in trauma emergency situations [24].
4.4 Hemodynamic and respiratory effects
Ketamine’s ability to promote central sympathetic stimulation and inhibition of 
neuronal catecholamine reuptake has brought upon its resurgence as an excellent 
sedation maintenance drug [7]. These effects favor hemodynamic stability. A pro-
spective double-blind controlled study compared the use of ketamine vs. fentanyl 
for sedation in the ICU. It was observed that patients on ketamine had an increased 
MAP and a decreased incidence of shock. This characteristic is what makes it an 
excellent choice for induction of anesthesia for potentially unstable cardiac patients, 
especially when combined with midazolam. This benefit was observed in patients 
with septic cardiomyopathy [8].
In addition, clinicians have adapted ‘ketofol,’ a combination of ketamine and 
propofol especially for sedation cases. Propofol when used alone can cause myocar-
dial depression and systemic vasodilation that both lead to hypotension, especially 
in a fasting patient. When propofol was used alone, it causesd a 20% reduction in 
systolic blood pressure in the first 5 and 10 minutes compare to ‘ketofol’ [10].
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In addition, Ketamine tends to relax bronchiole smooth muscles. Thus, it can 
protect asymptomatic patients with asthma from developing bronchospasm and it 
can also effectively relieve bronchospasm in patients who already have respiratory 
problems before anesthesia. In addition, it has been used as an analgo-sedative in 
patients with status asthmaticus, not responding to the usual therapeutic options; 
as this can reduce the need for mechanical ventilation [8]. A review of prospective 
and observational studies showed a noticeable increase in chest wall dynamics in 
patients with status asthmaticus. They noticed that patients receiving ketamine 
continuous infusion also had reducible wheezing and even reduced bronchodilator 
requirement [7]. It should also be noted that unlike opioids, it does not increase 
histamine release; further reducing the possibility of bronchospasm [8].
These benefits extend to the pediatric population. Research has shown ketofol 
use as an induction agent as an alternative to propofol led to better laryngeal mask 
airway (LMA) insertion in children. In addition, during the LMA the use of ketofol 
showed faster induction time, lower injection pain, better jaw relaxation, better 
full mouth opening, and less incidence and duration of apnea when compared 
to using propofol alone [25]. Another study showed that induction with adjunc-
tive use of ketamine and propofol, 1 mg/kg ketamine at induction and 5 mg/kg/h 
propofol infusion for maintenance for MRI sedation in children resulted in better 
induction quality, lower propofol infusion rate for maintenance, and faster time 
to full recovery [26]. Ketofol seems to have an effect that is dependent on the ratio 
of propofol to ketamine. In a clinical trial performed, it was determined that a 10:1 
propofol ketamine ratio seems to have the greatest benefit during surgery due to 
better hemodynamic stability maintenance and faster recovery time [27].
5. Ketamine and opioid free anesthesia
With the opioid epidemic in recent years, clinicians are exploring options to pro-
vide pain relief with reduced or no opioid administration. Although opioids provide 
excellent analgesia, they can also produce unpleasant adverse effects such as nausea, 
vomiting, tolerance, pruritis, hyperalgesia, urinary retention, constipation, respira-
tory depression and have an extremely high potential for abuse. Approximately 2 
million Americans use opioids for recreational purposes. According to the United 
State National Institute of Drug Abuse, overdose deaths involving prescription 
opioids rose from 3442 in 1999 to 17029 in 2017. Studies have shown that patients 
who consume high doses of opioids in the inpatient setting have a higher probability 
of report of increase opioid use after discharge. This is especially true for patients 
who leave the hospital with a prescription for opioids [28].
With regards to cancer pain control, the role of opioids has come into question in 
recent years as new data emerges about opioids, such as Morphine having pro tumor 
effects. Morphine may stimulate proliferation, facilitate metastasis, and promote 
angiogenesis leading to increased tumor burden. However, generalizations about 
these effects should not be extended to all opioids as research is still ongoing on this 
topic [29].
In recent years, clinicians are fast adopting Early Recovery After Surgery 
(ERAS) protocols that have an increased focus on a multimodal approach to pain 
control to reduce the consumption or even exposure to opioids. In the preopera-
tive setting drugs such as celecoxib, acetaminophen and gabapentin are being 
utilized to begin pain control even before surgical incision is made. In the operating 
room Ketamine, among others such as Dexmedetomidine, Intravenous Lidocaine, 
Intravenous Magnesium, are some of the drugs on the forefront to achieve opioid 
free or opioid reduced pain relief.
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In 2019 a study to evaluate the effect of Opioid Free Anesthesia (OFA) on 
post-operative morphine consumption and the post-operative course was initiated. 
Ketamine was used in both arms of OFA and Opioid Anesthesia (OA) for induction. 
A statistically significant result of reduced supplemental opioid consumption in the 
OFA group was observed (0.001). It should be noted, however, that ketamine was 
used in conjunction with lidocaine and dextromethorphan in the OFA group. In 
addition, the reduction in opioids used may also be due to reduced opioid tolerance. 
It was noted that postoperative pain scores did not differ between groups, indicat-
ing that OA and OFA provided comparable analgesia [30].
Multiple studies on the role of NMDA receptor antagonists in preventive analge-
sia have been reviewed. Preventive analgesia a concept in which the administration 
of a drug at any point in the perioperative period and the presumed associated 
reduction in central sensitization may reduce pain, analgesic consumption, or both 
beyond the clinical activity of the target drug. Their systemic review showed that 
ketamine and dextromethorphan produced significant preventive analgesic benefit 
in 58% and 67% of studies, respectively. In addition, a direct analgesic benefit of 
the drug occurred in the early postoperative period [5]. It can then be inferred that 
if pain is controlled early in surgery, then there may be reduced need for additional 
analgesic medications, including opioids.
A randomized, prospective, double blinded placebo- controlled study investi-
gating the efficacy of preemptive ketamine infusions in patients with chronic pain 
undergoing elective back surgery was conducted. These patients had a history of 
at least 6 weeks (about 1 and a half months) of opiate use. They demonstrated that 
intraoperative preventative ketamine reduced opiate consumption in the acute 
postoperative period by 37% in these patients. In addition, it seemed that these 
patients who received ketamine infusions had a reduced pain sensation in the PACU 
(post anesthesia care unit) and even 6 weeks in the post operative period, leading 
to a reduction in morphine consumption [31]. As previously discussed, this reduc-
tion in pain sensation is due to reduction central sensitization via NMDA receptor 
antagonism, reduction in opiate tolerance, and some impact on the balance of 
neurotransmitters. This concept of preemptive analgesia was further explored by 
studying the effects of preemptive doses of ketamine before laparoscopic cholecys-
tectomies at three doses; 1 mg.kg, 0.5 mg/kg and 0.25 mg/kg. In addition, research-
ers evaluated their effects on cardiovascular hemodynamics and hallucinations. 
There was a definitive role in reducing postoperative pain and analgesic require-
ment in patients. A low dose of 0.5 mg/kg was devoid of hemodynamic changes 
and hallucinations, making it the optimal dose for patients undergoing laparoscopic 
cholecystectomy [32].
Ketamine is being favored in bariatric surgery as obese patients tend to have 
obstructive sleep apnea and obesity hypoventilation syndrome that can be difficult 
to manage during induction and emergence of anesthesia. Due to its favorable 
stability on the cardiovascular system, respiratory system and gastrointestinal 
systems as detailed above. While only in a single case study, an opioid free anes-
thetic delivered to an obese lady with BMI of 50.1. She received an initial bolus of 
ketamine 5 mg·kg−1 was followed by a continuous infusion at 5 μg·kg−1 min−1. She 
underwent surgery without complication, rapidly met all extubation criteria, was 
never hypoxic, and was ambulating unassisted after 90 minutes in the recovery 
room without pain. She received ketorolac and IV Acetaminophen as the multi-
modal regimen. No opioids were used [33]. This case study lays the foundation for 
an excellent randomized double blinded study to improve outcomes in bariatric 
surgery. Furthermore TIVA with propofol, ketamine and dexmedetomidine (59 
patients) vs. opioids and volatile anesthetics (60 patients) and their effects on post-
operative nausea and vomiting (PONV) has been studied. Patients in both groups 
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had similar clinical characteristics, surgical procedure, and PONV risk scores 
and required similar amounts of postoperative opioid. 37.3% in the Opioid group 
compared to only 20% group reported PONV with a statistically difference (0.02). 
It was concluded that opioid-free TIVA is associated with a significant reduction in 
relative risk of PONV compared with balanced anesthesia [34].
Overall, OFA has gained in popularity to enhance early recovery and so spare 
opioids for the postoperative period. Pain is an extremely complex interaction of 
biological, cognitive, behavioral, cultural and environmental factors. Whether it 
is possible to deliver a safe and stable anesthesia without intraoperative opioids to 
many patients undergoing various surgical procedures. OFA still raises questions. 
Accurate monitoring to measure intraoperative nociception and guide the use of 
adjuvants is not available. Also, there is a need for procedure specific strategies as 
well as indications and contraindications to the technique. OFA does not seem to 
reduce the amounts of opioids prescribed at discharge which needs to be addressed 
and thought about by health care professionals.
6. Conclusion
Ketamine has made a strong resurgence as a versatile drug in the field of anes-
thesia. We reviewed the history of anesthesia from its discovery to its application 
as an anesthetic. In addition, we aimed to demonstrate how ketamine has favorable 
properties with regards to hemodynamics, its neuroprotective properties, psycho-
modulator effects, and anti-inflammatory effects. These favorable properties have 
made it one of the drugs on the forefront of the opioid free anesthesia concept dis-
cussed in this chapter. We remain excited about the ongoing research on Ketamine’s 
role in treatment of patient with Post Traumatic Stress Disorder and various other 
applications in the field of Anesthesia.
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